Home >> Marketplace Archives >> Genetic breast cancer risk testing

Genetic breast cancer risk testing

Print Friendly, PDF & Email

January 2015—Quest Diagnostics now offers BRC­Avantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.

BRCAvantage Plus screens for point mutations, deletions, and duplications in the BRCA1 and BRCA2 genes and in five additional genes—TP53, PTEN, CDH1, STK11, and PALB2. A key feature of BRCAvantage Plus, according to a company statement, is that physicians can order single gene tests as well as a comprehensive panel, depending on the specific clinical and family history. An additional reflex option automatically tests the five non-BRCA genes in cases where initial BRCA1 and BRCA2 mutation testing produces a negative result.

Quest Diagnostics, 866-436-3463


Check Also

Quest acquires two Texas labs, 7/17

July 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Tex., with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.